Details of the Drug

General Information of Drug (ID: DMZSDGX)

Drug Name

Dicyclomine

Synonyms

Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Functional bowel syndrome	DD91.0	Approved	[1]

Therapeutic Class

Anticholinergic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

309.5

Topological Polar Surface Area (xlogp)

5.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
Elimination: 79.5% of drug eliminated in the urine and 8.4% in the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.8 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.29731 micromolar/kg/day [4]
Vd: The volume of distribution (Vd) of drug is 3.65 L/kg [5]

Chemical Identifiers

Formula: C19H35NO2
IUPAC Name: 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
Canonical SMILES: CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
InChI: InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
InChIKey: CURUTKGFNZGFSE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3042
ChEBI ID: CHEBI:4514
CAS Number: 77-19-0
DrugBank ID: DB00804
TTD ID: D07XJM
VARIDT ID: DR00767
INTEDE ID: DR2280
ACDINA ID: D00194

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Antagonist	[6], [7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Functional bowel syndrome

ICD Disease Classification

DD91.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M1 (CHRM1)	DTT	CHRM1	5.59E-01	0.19	0.41

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dicyclomine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Dicyclomine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[17]
-----------

Coadministration of a Drug Treating the Disease Different from Dicyclomine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Dicyclomine when combined with Bethanechol.	Abnormal micturition [MF50]	[18]
Oliceridine	DM6MDCF	Moderate	Additive antimotility effects by the combination of Dicyclomine and Oliceridine.	Acute pain [MG31]	[19]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Memantine.	Alzheimer disease [8A20]	[21]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Dicyclomine when combined with Rivastigmine.	Alzheimer disease [8A20]	[22]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Dicyclomine when combined with Donepezil.	Alzheimer disease [8A20]	[22]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[21]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Cariprazine.	Bipolar disorder [6A60]	[21]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Dicyclomine and Loperamide.	Bowel habit change [ME05]	[23]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Dicyclomine when combined with Acetylcholine.	Cataract [9B10]	[24]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[25]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[25]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[25]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Dicyclomine and Dihydrocodeine.	Chronic pain [MG30]	[26]
Remifentanil	DMZTXCH	Moderate	Additive antimotility effects by the combination of Dicyclomine and Remifentanil.	Corneal disease [9A76-9A78]	[19]
Arbutamine	DMCY8AF	Moderate	Increased risk of rapid heart rate by the combination of Dicyclomine and Arbutamine.	Coronary atherosclerosis [BA80]	[27]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Dicyclomine and Ethanol.	Cystitis [GC00]	[28]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[21]
Isocarboxazid	DMAF1NB	Minor	Additive anticholinergic effects by the combination of Dicyclomine and Isocarboxazid.	Depression [6A70-6A7Z]	[21]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and OPC-34712.	Depression [6A70-6A7Z]	[21]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Clomipramine.	Depression [6A70-6A7Z]	[21]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Doxepin.	Depression [6A70-6A7Z]	[21]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Maprotiline.	Depression [6A70-6A7Z]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Mepenzolate.	Digestive system disease [DE2Z]	[21]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Oxybutynine.	Discovery agent [N.A.]	[21]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Dicyclomine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[29]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Solifenacin.	Functional bladder disorder [GC50]	[21]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Tolterodine.	Functional bladder disorder [GC50]	[21]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Dicyclomine due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[30]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Dicyclomine when combined with Pilocarpine.	Glaucoma [9C61]	[18]
Carvedilol	DMHTEAO	Moderate	Altered absorption of Dicyclomine due to GI dynamics variation caused by Carvedilol.	Heart failure [BD10-BD1Z]	[31]
Chlorothiazide	DMLHESP	Minor	Altered absorption of Dicyclomine due to GI dynamics variation caused by Chlorothiazide.	Heart failure [BD10-BD1Z]	[32]
Acebutolol	DM0TI4U	Moderate	Altered absorption of Dicyclomine due to GI dynamics variation caused by Acebutolol.	Hypertension [BA00-BA04]	[31]
Penbutolol	DM4ES8F	Moderate	Antagonize the effect of Dicyclomine when combined with Penbutolol.	Hypertension [BA00-BA04]	[31]
Pindolol	DMD2NV7	Moderate	Altered absorption of Dicyclomine due to GI dynamics variation caused by Pindolol.	Hypertension [BA00-BA04]	[31]
Indapamide	DMGN1PW	Minor	Altered absorption of Dicyclomine due to GI dynamics variation caused by Indapamide.	Hypertension [BA00-BA04]	[32]
Trichlormethiazide	DMHAQCO	Minor	Altered absorption of Dicyclomine due to GI dynamics variation caused by Trichlormethiazide.	Hypertension [BA00-BA04]	[32]
Hydrochlorothiazide	DMUSZHD	Minor	Altered absorption of Dicyclomine due to GI dynamics variation caused by Hydrochlorothiazide.	Hypertension [BA00-BA04]	[32]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[21]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Amantadine.	Influenza [1E30-1E32]	[33]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Dicyclomine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[22]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Dicyclomine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[34]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Dicyclomine and Lasmiditan.	Migraine [8A80]	[35]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Dicyclomine and Flibanserin.	Mood disorder [6A60-6E23]	[36]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Dicyclomine when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[37]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Dicyclomine when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[37]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Phenindamine.	Nasopharyngitis [CA00]	[21]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Dimenhydrinate.	Nausea/vomiting [MD90]	[21]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Promethazine.	Nausea/vomiting [MD90]	[21]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Cyclizine.	Nausea/vomiting [MD90]	[21]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Dicyclomine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[38]
Polythiazide	DMCH80F	Minor	Altered absorption of Dicyclomine due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[32]
Levomethadyl Acetate	DM06HG5	Moderate	Additive antimotility effects by the combination of Dicyclomine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[26]
Oxymorphone	DM65AGJ	Moderate	Additive antimotility effects by the combination of Dicyclomine and Oxymorphone.	Pain [MG30-MG3Z]	[19]
Levorphanol	DMGS80V	Moderate	Additive antimotility effects by the combination of Dicyclomine and Levorphanol.	Pain [MG30-MG3Z]	[19]
Dezocine	DMJDB0Y	Moderate	Additive antimotility effects by the combination of Dicyclomine and Dezocine.	Pain [MG30-MG3Z]	[19]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Flavoxate.	Pain [MG30-MG3Z]	[21]
Nalbuphine	DMOSQGU	Moderate	Additive antimotility effects by the combination of Dicyclomine and Nalbuphine.	Pain [MG30-MG3Z]	[19]
Buprenorphine	DMPRI8G	Moderate	Additive antimotility effects by the combination of Dicyclomine and Buprenorphine.	Pain [MG30-MG3Z]	[19]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Biperiden.	Parkinsonism [8A00]	[21]
Levodopa	DMN3E57	Moderate	Altered absorption of Dicyclomine due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[39]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Orphenadrine.	Parkinsonism [8A00]	[21]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Methylscopolamine.	Peptic ulcer [DA61]	[21]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[21]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Mesoridazine.	Schizophrenia [6A20]	[21]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Iloperidone.	Schizophrenia [6A20]	[21]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Paliperidone.	Schizophrenia [6A20]	[21]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Perphenazine.	Schizophrenia [6A20]	[21]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Thiothixene.	Schizophrenia [6A20]	[21]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Trifluoperazine.	Schizophrenia [6A20]	[21]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Asenapine.	Schizophrenia [6A20]	[21]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Pimozide.	Schizophrenia [6A20]	[21]
Fentanyl	DM8WAHT	Moderate	Additive antimotility effects by the combination of Dicyclomine and Fentanyl.	Sensation disturbance [MB40]	[19]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Dicyclomine due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[40]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[21]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[21]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[21]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Dicyclomine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[21]
-----------


⏷ Show the Full List of 83 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
FD&C red no. 4	E00356	62542	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
FD&C red no. 3	E00629	Not Available	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dicyclomine 10 mg capsule	10 mg	Oral Capsule	Oral
Dicyclomine 20 mg tablet	20 mg	Oral Tablet	Oral
Dicyclomine 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA Approved Drug Products: NORVIR (ritonavir) Capsules, Soft Gelatin for Oral use
3	Metabolic dynamics of dicyclomine hydrochloride in man as influenced by various dose schedules and formulations Toxicology and Applied Pharmacology. 1967 Dec 18;13(1):16-23.
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	FDA Approved Drug Products: Dicyclomine Oral Capsules, Oral Tablets, and Intramuscular Injections
6	[Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11.
7	Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Dec;87(16):3658-70.
8	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
9	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
10	Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
11	The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
12	Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
13	Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
14	Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
15	Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
16	Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
17	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
18	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
19	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
20	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
21	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
22	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
23	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
24	Multum Information Services, Inc. Expert Review Panel.
25	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
26	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
27	Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
28	Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
29	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
30	Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
31	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
33	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
34	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
35	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
36	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
37	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
38	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
39	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
40	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.